Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 60

1.

Expression of L1 retrotransposon open reading frame protein 1 in gynecologic cancers.

Xia Z, Cochrane DR, Tessier-Coutier B, Leung S, Karnezis AN, Cheng AS, Farnell DA, Magrill J, Schmidt D, Kommoss S, Kommoss FKF, Kommoss F, McAlpine JN, Gilks CB, Koebel M, Rabban JT, Huntsman DG.

Hum Pathol. 2019 Jun 18;92:39-47. doi: 10.1016/j.humpath.2019.06.001. [Epub ahead of print]

PMID:
31220479
2.

DICER1 and FOXL2 Mutation Status Correlates With Clinicopathologic Features in Ovarian Sertoli-Leydig Cell Tumors.

Karnezis AN, Wang Y, Keul J, Tessier-Cloutier B, Magrill J, Kommoss S, Senz J, Yang W, Proctor L, Schmidt D, Clement PB, Gilks CB, Huntsman DG, Kommoss F.

Am J Surg Pathol. 2019 May;43(5):628-638. doi: 10.1097/PAS.0000000000001232.

PMID:
30986800
3.

Histone Deacetylase Inhibitors Synergize with Catalytic Inhibitors of EZH2 to Exhibit Antitumor Activity in Small Cell Carcinoma of the Ovary, Hypercalcemic Type.

Wang Y, Chen SY, Colborne S, Lambert G, Shin CY, Santos ND, Orlando KA, Lang JD, Hendricks WPD, Bally MB, Karnezis AN, Hass R, Underhill TM, Morin GB, Trent JM, Weissman BE, Huntsman DG.

Mol Cancer Ther. 2018 Dec;17(12):2767-2779. doi: 10.1158/1535-7163.MCT-18-0348. Epub 2018 Sep 19.

PMID:
30232145
4.

Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles.

Magrill J, Karnezis AN, Tessier-Cloutier B, Talhouk A, Kommoss S, Cochrane D, Chow C, Cheng A, Soslow R, Hauptmann S, du Bois A, Pfisterer J, Gilks CB, Huntsman DG, Kommoss F.

Int J Gynecol Pathol. 2019 Nov;38(6):552-561. doi: 10.1097/PGP.0000000000000538.

PMID:
30059451
5.

L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile.

Kommoss FK, Karnezis AN, Kommoss F, Talhouk A, Taran FA, Staebler A, Gilks CB, Huntsman DG, Krämer B, Brucker SY, McAlpine JN, Kommoss S.

Br J Cancer. 2018 Aug;119(4):480-486. doi: 10.1038/s41416-018-0187-6. Epub 2018 Jul 27.

6.

Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer.

Zhang AW, McPherson A, Milne K, Kroeger DR, Hamilton PT, Miranda A, Funnell T, Little N, de Souza CPE, Laan S, LeDoux S, Cochrane DR, Lim JLP, Yang W, Roth A, Smith MA, Ho J, Tse K, Zeng T, Shlafman I, Mayo MR, Moore R, Failmezger H, Heindl A, Wang YK, Bashashati A, Grewal DS, Brown SD, Lai D, Wan ANC, Nielsen CB, Huebner C, Tessier-Cloutier B, Anglesio MS, Bouchard-Côté A, Yuan Y, Wasserman WW, Gilks CB, Karnezis AN, Aparicio S, McAlpine JN, Huntsman DG, Holt RA, Nelson BH, Shah SP.

Cell. 2018 Jun 14;173(7):1755-1769.e22. doi: 10.1016/j.cell.2018.03.073. Epub 2018 May 10.

7.

High Frequency of Ovarian Cyst Development in Vhl2B/+;Snf5+/- Mice.

Kuwahara Y, Kennedy LM, Karnezis AN, Mora-Blanco EL, Rogers AB, Fletcher CD, Huntsman DG, Roberts CWM, Rathmell WK, Weissman BE.

Am J Pathol. 2018 Jul;188(7):1510-1516. doi: 10.1016/j.ajpath.2018.03.010. Epub 2018 Apr 22.

8.

DICER1 hot-spot mutations in ovarian gynandroblastoma.

Wang Y, Karnezis AN, Magrill J, Tessier-Cloutier B, Lum A, Senz J, Gilks CB, McCluggage WG, Huntsman DG, Kommoss F.

Histopathology. 2018 Aug;73(2):306-313. doi: 10.1111/his.13630. Epub 2018 Jun 5.

PMID:
29660837
9.

Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.

Lang JD, Hendricks WPD, Orlando KA, Yin H, Kiefer J, Ramos P, Sharma R, Pirrotte P, Raupach EA, Sereduk C, Tang N, Liang WS, Washington M, Facista SJ, Zismann VL, Cousins EM, Major MB, Wang Y, Karnezis AN, Sekulic A, Hass R, Vanderhyden BC, Nair P, Weissman BE, Huntsman DG, Trent JM.

Clin Cancer Res. 2018 Apr 15;24(8):1932-1943. doi: 10.1158/1078-0432.CCR-17-1928. Epub 2018 Feb 9.

10.

Bartholin Gland Carcinoma: Clinicopathologic Features, Including p16 Expression and Clinical Outcome.

Nazeran T, Cheng AS, Karnezis AN, Tinker AV, Gilks CB.

Int J Gynecol Pathol. 2019 Mar;38(2):189-195. doi: 10.1097/PGP.0000000000000489.

PMID:
29406447
11.

Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.

Garg K, Karnezis AN, Rabban JT.

Pathology. 2018 Feb;50(2):238-256. doi: 10.1016/j.pathol.2017.10.009. Epub 2018 Jan 17. Review.

PMID:
29373116
12.

Evaluation of endometrial carcinoma prognostic immunohistochemistry markers in the context of molecular classification.

Karnezis AN, Leung S, Magrill J, McConechy MK, Yang W, Chow C, Kobel M, Lee CH, Huntsman DG, Talhouk A, Kommoss F, Gilks CB, McAlpine JN.

J Pathol Clin Res. 2017 Oct 14;3(4):279-293. doi: 10.1002/cjp2.82. eCollection 2017 Oct.

13.

Detection and genomic characterization of a mammary-like adenocarcinoma.

Grewal JK, Eirew P, Jones M, Chiu K, Tessier-Cloutier B, Karnezis AN, Karsan A, Mungall A, Zhou C, Yip S, Tinker AV, Laskin J, Marra M, Jones SJM.

Cold Spring Harb Mol Case Stud. 2017 Nov 21;3(6). pii: a002170. doi: 10.1101/mcs.a002170. Print 2017 Nov.

14.

Preclinical Models of Ovarian Cancer: Pathogenesis, Problems, and Implications for Prevention.

Karnezis AN, Cho KR.

Clin Obstet Gynecol. 2017 Dec;60(4):789-800. doi: 10.1097/GRF.0000000000000312. Review.

15.

Clear cell and endometrioid carcinomas: are their differences attributable to distinct cells of origin?

Cochrane DR, Tessier-Cloutier B, Lawrence KM, Nazeran T, Karnezis AN, Salamanca C, Cheng AS, McAlpine JN, Hoang LN, Gilks CB, Huntsman DG.

J Pathol. 2017 Sep;243(1):26-36. doi: 10.1002/path.4934. Epub 2017 Aug 7.

PMID:
28678427
16.

The histone methyltransferase EZH2 is a therapeutic target in small cell carcinoma of the ovary, hypercalcaemic type.

Wang Y, Chen SY, Karnezis AN, Colborne S, Santos ND, Lang JD, Hendricks WP, Orlando KA, Yap D, Kommoss F, Bally MB, Morin GB, Trent JM, Weissman BE, Huntsman DG.

J Pathol. 2017 Jul;242(3):371-383. doi: 10.1002/path.4912. Epub 2017 Jun 2.

PMID:
28444909
17.

Genomic consequences of aberrant DNA repair mechanisms stratify ovarian cancer histotypes.

Wang YK, Bashashati A, Anglesio MS, Cochrane DR, Grewal DS, Ha G, McPherson A, Horlings HM, Senz J, Prentice LM, Karnezis AN, Lai D, Aniba MR, Zhang AW, Shumansky K, Siu C, Wan A, McConechy MK, Li-Chang H, Tone A, Provencher D, de Ladurantaye M, Fleury H, Okamoto A, Yanagida S, Yanaihara N, Saito M, Mungall AJ, Moore R, Marra MA, Gilks CB, Mes-Masson AM, McAlpine JN, Aparicio S, Huntsman DG, Shah SP.

Nat Genet. 2017 Jun;49(6):856-865. doi: 10.1038/ng.3849. Epub 2017 Apr 24.

PMID:
28436987
18.

Human papillomavirus (HPV)-independent vulvar squamous cell carcinoma has a worse prognosis than HPV-associated disease: a retrospective cohort study.

McAlpine JN, Leung SCY, Cheng A, Miller D, Talhouk A, Gilks CB, Karnezis AN.

Histopathology. 2017 Aug;71(2):238-246. doi: 10.1111/his.13205. Epub 2017 May 23.

PMID:
28257152
19.

Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.

Talhouk A, McConechy MK, Leung S, Yang W, Lum A, Senz J, Boyd N, Pike J, Anglesio M, Kwon JS, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.

20.

Of mice and women - Non-ovarian origins of "ovarian" cancer.

Karnezis AN, Cho KR.

Gynecol Oncol. 2017 Jan;144(1):5-7. doi: 10.1016/j.ygyno.2016.11.039. Epub 2016 Nov 24. No abstract available.

PMID:
27890279
21.

The disparate origins of ovarian cancers: pathogenesis and prevention strategies.

Karnezis AN, Cho KR, Gilks CB, Pearce CL, Huntsman DG.

Nat Rev Cancer. 2017 Jan;17(1):65-74. doi: 10.1038/nrc.2016.113. Epub 2016 Nov 25. Review.

PMID:
27885265
22.

Impact of oviductal versus ovarian epithelial cell of origin on ovarian endometrioid carcinoma phenotype in the mouse.

Wu R, Zhai Y, Kuick R, Karnezis AN, Garcia P, Naseem A, Hu TC, Fearon ER, Cho KR.

J Pathol. 2016 Nov;240(3):341-351. doi: 10.1002/path.4783.

23.

Quantitative Profiling of Single Formalin Fixed Tumour Sections: proteomics for translational research.

Hughes CS, McConechy MK, Cochrane DR, Nazeran T, Karnezis AN, Huntsman DG, Morin GB.

Sci Rep. 2016 Oct 7;6:34949. doi: 10.1038/srep34949.

24.

Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.

Coatham M, Li X, Karnezis AN, Hoang LN, Tessier-Cloutier B, Meng B, Soslow RA, Blake Gilks C, Huntsman DG, Stewart CJ, Postovit LM, Köbel M, Lee CH.

Mod Pathol. 2016 Dec;29(12):1586-1593. doi: 10.1038/modpathol.2016.156. Epub 2016 Aug 26.

25.

Immunophenotypic features of dedifferentiated endometrial carcinoma - insights from BRG1/INI1-deficient tumours.

Hoang LN, Lee YS, Karnezis AN, Tessier-Cloutier B, Almandani N, Coatham M, Gilks CB, Soslow RA, Stewart CJ, Köbel M, Lee CH.

Histopathology. 2016 Oct;69(4):560-9. doi: 10.1111/his.12989. Epub 2016 Jul 5.

26.

Loss of SMARCA4 (BRG1) protein expression as determined by immunohistochemistry in small-cell carcinoma of the ovary, hypercalcaemic type distinguishes these tumours from their mimics.

Clarke BA, Witkowski L, Ton Nu TN, Shaw PA, Gilks CB, Huntsman D, Karnezis AN, Sebire N, Lamovec J, Roth LM, Stewart CJ, Hasselblatt M, Foulkes WD, McCluggage WG.

Histopathology. 2016 Nov;69(5):727-738. doi: 10.1111/his.12988. Epub 2016 Jul 28.

PMID:
27100627
27.

The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type.

Witkowski L, Goudie C, Ramos P, Boshari T, Brunet JS, Karnezis AN, Longy M, Knost JA, Saloustros E, McCluggage WG, Stewart CJR, Hendricks WPD, Cunliffe H, Huntsman DG, Pautier P, Levine DA, Trent JM, Berchuck A, Hasselblatt M, Foulkes WD.

Gynecol Oncol. 2016 Jun;141(3):454-460. doi: 10.1016/j.ygyno.2016.03.013. Epub 2016 Mar 19.

PMID:
26975901
28.

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.

Anglesio MS, Wang YK, Maassen M, Horlings HM, Bashashati A, Senz J, Mackenzie R, Grewal DS, Li-Chang H, Karnezis AN, Sheffield BS, McConechy MK, Kommoss F, Taran FA, Staebler A, Shah SP, Wallwiener D, Brucker S, Gilks CB, Kommoss S, Huntsman DG.

J Natl Cancer Inst. 2016 Feb 1;108(6):djv428. doi: 10.1093/jnci/djv428. Print 2016 Jun.

PMID:
26832771
29.

Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.

Karnezis AN, Hoang LN, Coatham M, Ravn S, Almadani N, Tessier-Cloutier B, Irving J, Meng B, Li X, Chow C, McAlpine J, Kuo KT, Mao TL, Djordjevic B, Soslow RA, Huntsman DG, Blake Gilks C, Köbel M, Lee CH.

Mod Pathol. 2016 Mar;29(3):302-14. doi: 10.1038/modpathol.2015.155. Epub 2016 Jan 8.

30.

p16 Immunostaining Allows for Accurate Subclassification of Vulvar Squamous Cell Carcinoma Into HPV-Associated and HPV-Independent Cases.

Cheng AS, Karnezis AN, Jordan S, Singh N, McAlpine JN, Gilks CB.

Int J Gynecol Pathol. 2016 Jul;35(4):385-93. doi: 10.1097/PGP.0000000000000263.

PMID:
26630231
31.

Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.

Karnezis AN, Wang Y, Ramos P, Hendricks WP, Oliva E, D'Angelo E, Prat J, Nucci MR, Nielsen TO, Chow C, Leung S, Kommoss F, Kommoss S, Silva A, Ronnett BM, Rabban JT, Bowtell DD, Weissman BE, Trent JM, Gilks CB, Huntsman DG.

J Pathol. 2016 Feb;238(3):389-400. doi: 10.1002/path.4633. Epub 2015 Dec 21.

32.

A clinically applicable molecular-based classification for endometrial cancers.

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N, Yang W, Senz J, Boyd N, Karnezis AN, Huntsman DG, Gilks CB, McAlpine JN.

Br J Cancer. 2015 Jul 14;113(2):299-310. doi: 10.1038/bjc.2015.190. Epub 2015 Jun 30.

33.

Comprehensive genomic profiles of small cell lung cancer.

George J, Lim JS, Jang SJ, Cun Y, Ozretić L, Kong G, Leenders F, Lu X, Fernández-Cuesta L, Bosco G, Müller C, Dahmen I, Jahchan NS, Park KS, Yang D, Karnezis AN, Vaka D, Torres A, Wang MS, Korbel JO, Menon R, Chun SM, Kim D, Wilkerson M, Hayes N, Engelmann D, Pützer B, Bos M, Michels S, Vlasic I, Seidel D, Pinther B, Schaub P, Becker C, Altmüller J, Yokota J, Kohno T, Iwakawa R, Tsuta K, Noguchi M, Muley T, Hoffmann H, Schnabel PA, Petersen I, Chen Y, Soltermann A, Tischler V, Choi CM, Kim YH, Massion PP, Zou Y, Jovanovic D, Kontic M, Wright GM, Russell PA, Solomon B, Koch I, Lindner M, Muscarella LA, la Torre A, Field JK, Jakopovic M, Knezevic J, Castaños-Vélez E, Roz L, Pastorino U, Brustugun OT, Lund-Iversen M, Thunnissen E, Köhler J, Schuler M, Botling J, Sandelin M, Sanchez-Cespedes M, Salvesen HB, Achter V, Lang U, Bogus M, Schneider PM, Zander T, Ansén S, Hallek M, Wolf J, Vingron M, Yatabe Y, Travis WD, Nürnberg P, Reinhardt C, Perner S, Heukamp L, Büttner R, Haas SA, Brambilla E, Peifer M, Sage J, Thomas RK.

Nature. 2015 Aug 6;524(7563):47-53. doi: 10.1038/nature14664. Epub 2015 Jul 13.

34.

Multifocal endometriotic lesions associated with cancer are clonal and carry a high mutation burden.

Anglesio MS, Bashashati A, Wang YK, Senz J, Ha G, Yang W, Aniba MR, Prentice LM, Farahani H, Li Chang H, Karnezis AN, Marra MA, Yong PJ, Hirst M, Gilks B, Shah SP, Huntsman DG.

J Pathol. 2015 Jun;236(2):201-9. doi: 10.1002/path.4516. Epub 2015 Mar 23.

35.

Small cell carcinoma of the ovary, hypercalcemic type, displays frequent inactivating germline and somatic mutations in SMARCA4.

Ramos P, Karnezis AN, Craig DW, Sekulic A, Russell ML, Hendricks WP, Corneveaux JJ, Barrett MT, Shumansky K, Yang Y, Shah SP, Prentice LM, Marra MA, Kiefer J, Zismann VL, McEachron TA, Salhia B, Prat J, D'Angelo E, Clarke BA, Pressey JG, Farley JH, Anthony SP, Roden RB, Cunliffe HE, Huntsman DG, Trent JM.

Nat Genet. 2014 May;46(5):427-9. doi: 10.1038/ng.2928. Epub 2014 Mar 23.

36.

RAS transformation requires CUX1-dependent repair of oxidative DNA damage.

Ramdzan ZM, Vadnais C, Pal R, Vandal G, Cadieux C, Leduy L, Davoudi S, Hulea L, Yao L, Karnezis AN, Paquet M, Dankort D, Nepveu A.

PLoS Biol. 2014 Mar 11;12(3):e1001807. doi: 10.1371/journal.pbio.1001807. eCollection 2014 Mar.

37.

Association of tumor morphology with mismatch-repair protein status in older endometrial cancer patients: implications for universal versus selective screening strategies for Lynch syndrome.

Rabban JT, Calkins SM, Karnezis AN, Grenert JP, Blanco A, Crawford B, Chen LM.

Am J Surg Pathol. 2014 Jun;38(6):793-800. doi: 10.1097/PAS.0000000000000177.

PMID:
24503759
38.

Loss of the tumor suppressor SMARCA4 in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

Ramos P, Karnezis AN, Hendricks WP, Wang Y, Tembe W, Zismann VL, Legendre C, Liang WS, Russell ML, Craig DW, Farley JH, Monk BJ, Anthony SP, Sekulic A, Cunliffe HE, Huntsman DG, Trent JM.

Rare Dis. 2014 Nov 3;2(1):e967148. doi: 10.4161/2167549X.2014.967148. eCollection 2014.

39.

Pilocytic astrocytomas of the optic nerve and their relation to pilocytic astrocytomas elsewhere in the central nervous system.

Reis GF, Bloomer MM, Perry A, Phillips JJ, Grenert JP, Karnezis AN, Tihan T.

Mod Pathol. 2013 Oct;26(10):1279-87. doi: 10.1038/modpathol.2013.79. Epub 2013 May 24.

40.

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors.

Altman AD, Nelson GS, Ghatage P, McIntyre JB, Capper D, Chu P, Nation JG, Karnezis AN, Han G, Kalloger SE, Köbel M.

Mod Pathol. 2013 Sep;26(9):1255-63. doi: 10.1038/modpathol.2013.55. Epub 2013 Apr 5.

41.

Breast fibroblasts modulate early dissemination, tumorigenesis, and metastasis through alteration of extracellular matrix characteristics.

Dumont N, Liu B, Defilippis RA, Chang H, Rabban JT, Karnezis AN, Tjoe JA, Marx J, Parvin B, Tlsty TD.

Neoplasia. 2013 Mar;15(3):249-62.

42.

Inhibition of Myc family proteins eradicates KRas-driven lung cancer in mice.

Soucek L, Whitfield JR, Sodir NM, Massó-Vallés D, Serrano E, Karnezis AN, Swigart LB, Evan GI.

Genes Dev. 2013 Mar 1;27(5):504-13. doi: 10.1101/gad.205542.112.

43.

Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.

Karnezis AN, Aysal A, Zaloudek CJ, Rabban JT.

Am J Surg Pathol. 2013 Jan;37(1):24-37. doi: 10.1097/PAS.0b013e31826a5399.

PMID:
23108017
44.

A crucial requirement for Hedgehog signaling in small cell lung cancer.

Park KS, Martelotto LG, Peifer M, Sos ML, Karnezis AN, Mahjoub MR, Bernard K, Conklin JF, Szczepny A, Yuan J, Guo R, Ospina B, Falzon J, Bennett S, Brown TJ, Markovic A, Devereux WL, Ocasio CA, Chen JK, Stearns T, Thomas RK, Dorsch M, Buonamici S, Watkins DN, Peacock CD, Sage J.

Nat Med. 2011 Oct 9;17(11):1504-8. doi: 10.1038/nm.2473.

45.

Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression.

Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME, Karnezis AN, Attardi LD.

Cell. 2011 May 13;145(4):571-83. doi: 10.1016/j.cell.2011.03.035.

46.

Endogenous Myc maintains the tumor microenvironment.

Sodir NM, Swigart LB, Karnezis AN, Hanahan D, Evan GI, Soucek L.

Genes Dev. 2011 May 1;25(9):907-16. doi: 10.1101/gad.2038411. Epub 2011 Apr 8.

47.

Junctional epithelial zones of the fallopian tube: cancer hotspots?

Rabban JT, Karnezis AN, Zaloudek CJ.

Int J Gynecol Pathol. 2011 Jan;30(1):1-3. doi: 10.1097/PGP.0b013e318200e370. No abstract available.

PMID:
21131841
48.

Selective activation of p53-mediated tumour suppression in high-grade tumours.

Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F, Brown Swigart L, Pham DM, Seo Y, Evan GI, Martins CP.

Nature. 2010 Nov 25;468(7323):567-71. doi: 10.1038/nature09526.

49.

Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma.

Schaffer BE, Park KS, Yiu G, Conklin JF, Lin C, Burkhart DL, Karnezis AN, Sweet-Cordero EA, Sage J.

Cancer Res. 2010 May 15;70(10):3877-83. doi: 10.1158/0008-5472.CAN-09-4228. Epub 2010 Apr 20.

50.

Braf(V600E) cooperates with Pten loss to induce metastatic melanoma.

Dankort D, Curley DP, Cartlidge RA, Nelson B, Karnezis AN, Damsky WE Jr, You MJ, DePinho RA, McMahon M, Bosenberg M.

Nat Genet. 2009 May;41(5):544-52. doi: 10.1038/ng.356. Epub 2009 Mar 12.

Supplemental Content

Loading ...
Support Center